RZLT vs. JANX, EVO, MESO, VERA, OCUL, TVTX, BGM, GPCR, CVAC, and CALT
Should you be buying Rezolute stock or one of its competitors? The main competitors of Rezolute include Janux Therapeutics (JANX), Evotec (EVO), Mesoblast (MESO), Vera Therapeutics (VERA), Ocular Therapeutix (OCUL), Travere Therapeutics (TVTX), BGM Group (BGM), Structure Therapeutics (GPCR), CureVac (CVAC), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry.
Rezolute vs. Its Competitors
Rezolute (NASDAQ:RZLT) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.
Rezolute has higher earnings, but lower revenue than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.
Rezolute has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.97, meaning that its stock price is 197% more volatile than the S&P 500.
83.0% of Rezolute shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 18.4% of Rezolute shares are held by insiders. Comparatively, 29.4% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Rezolute had 5 more articles in the media than Janux Therapeutics. MarketBeat recorded 9 mentions for Rezolute and 4 mentions for Janux Therapeutics. Rezolute's average media sentiment score of 1.59 beat Janux Therapeutics' score of 0.62 indicating that Rezolute is being referred to more favorably in the media.
Rezolute has a net margin of 0.00% compared to Janux Therapeutics' net margin of -463.91%. Janux Therapeutics' return on equity of -9.29% beat Rezolute's return on equity.
Rezolute presently has a consensus target price of $11.83, suggesting a potential upside of 165.32%. Janux Therapeutics has a consensus target price of $95.25, suggesting a potential upside of 312.34%. Given Janux Therapeutics' higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than Rezolute.
Summary
Rezolute and Janux Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Rezolute News Delivered to You Automatically
Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RZLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rezolute Competitors List
Related Companies and Tools
This page (NASDAQ:RZLT) was last updated on 7/1/2025 by MarketBeat.com Staff
